AtriCure Reports Third Quarter 2020 Financial Results

Rhea-AI Summary

AtriCure, Inc. (Nasdaq: ATRC) announced its third quarter 2020 results, reporting revenue of $54.8 million, a decrease of 3.3% year-over-year, largely due to the COVID-19 pandemic affecting surgical procedures. U.S. revenue fell by 3.1% to $44.7 million, while international revenue dropped 4.1% to $10.1 million. Gross profit was $40.3 million with a gross margin of 73.7%. The net loss per share improved to $0.11 from $0.25 in Q3 2019. For Q4 2020, the company expects revenue between $56 million and $60 million, with a full-year guidance of $205 million to $209 million.

Positive

• Adjusted EBITDA turned positive at $4.2 million compared to a loss of $2.2 million in Q3 2019.
• Net loss per share improved to $0.11 from $0.25 in the same quarter last year.

Negative

• Third quarter revenue decreased by 3.3% year-over-year due to the impact of COVID-19.
• Projected full-year adjusted EBITDA loss expected at approximately $10 million.

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2020 financial results.

“We are pleased with our third quarter performance and the improving trajectory of our business, which reflect the commitment of our team and underlying demand in our core markets,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “We are continuing to make significant progress on our strategic initiatives and are on the forefront of meaningfully expanding our addressable market opportunity.”

Third Quarter 2020 Financial Results

Revenue for the third quarter of 2020 was $54.8 million, a decrease of $1.9 million or 3.3% (a decrease of 3.9% on a constant currency basis), compared to third quarter 2019 revenue, due to the global decline in surgical procedures as a result of the COVID-19 pandemic. U.S. revenue decreased 3.1% to $44.7 million, and international revenue decreased 4.1% to $10.1 million, (a decrease of 7.2% on a constant currency basis), compared to third quarter 2019 revenue.

Gross profit for the third quarter of 2020 was $40.3 million compared to $41.8 million for the third quarter of 2019. Gross margin for the third quarter of 2020 remained relatively consistent at 73.7% compared to 73.8% in the third quarter of 2019, reflecting normal manufacturing operations during both periods.

Loss from operations for the third quarter of 2020 was $4.0 million, compared to $8.6 million for the third quarter of 2019. Net loss per share was $0.11 for the third quarter of 2020 compared to $0.25 for the third quarter of 2019. Adjusted EBITDA was a positive $4.2 million for the third quarter of 2020 compared to a loss of $2.2 million for the third quarter of 2019. Adjusted loss per share for the third quarter of 2020 was $0.11 compared to an adjusted loss per share of $0.33 for the third quarter of 2019.

Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP measures. We discuss these non-GAAP measures and provide reconciliations to GAAP measures later in this release.

2020 Financial Guidance

Management expects revenue to be $56 million to $60 million for the fourth quarter of 2020 and $205 million to $209 million for the full year 2020. Full year adjusted EBITDA loss is expected to be approximately $10 million.

Incrementally higher or lower impact from the on-going global pandemic could cause forecasts for fourth quarter and full year 2020 to differ materially than these projections.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 5, 2020 to discuss its third quarter 2020 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 8584906. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator^® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit http://www.atricure.com/fls as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We do not undertake to update our forward-looking statements. Actual results could differ materially.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Revenue reported on a constant currency basis is a non-GAAP measure and is calculated by applying previous period foreign currency exchange rates, which are determined by the average daily Euro to Dollar exchange rate, to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors.

Adjusted EBITDA is calculated as Net loss before other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, acquisition costs, and change in fair value of contingent consideration liabilities. Management believes in order to properly understand the short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning, and previously used adjusted EBITDA as a performance metric in the annual incentive plan. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Loss) (Adjusted EBITDA)” later in this release.

Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments to expenses related to the adjustment in value of contingent consideration liabilities. Management believes this metric provides a better measure of comparability of results between periods, as such adjustments can be significant and vary in value and are not reflective of our core business. A reconciliation of adjusted loss per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business.

ATRICURE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Amounts)
(Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2020				2019				2020				2019
United States Revenue:
Open ablation	$	19,911			$	19,754			$	54,679			$	59,311
Minimally invasive ablation		6,979				9,006				18,295				25,860
Appendage management		17,430				16,907				47,870				49,075
Total ablation and appendage management		44,320				45,667				120,844				134,246
Valve tools		381				456				994				2,046
Total United States		44,701				46,123				121,838				136,292
International Revenue:
Open ablation		4,907				5,850				13,766				18,942
Minimally invasive ablation		1,692				2,058				4,346				6,122
Appendage management		3,445				2,532				8,778				7,963
Total ablation and appendage management		10,044				10,440				26,890				33,027
Valve tools		12				51				78				167
Total international		10,056				10,491				26,968				33,194
Total revenue		54,757				56,614				148,806				169,486
Cost of revenue		14,423				14,817				41,934				43,925
Gross profit		40,334				41,797				106,872				125,561
Operating expenses:
Research and development expenses		10,576				10,154				32,199				28,134
Selling, general and administrative expenses		33,749				40,280				101,403				115,223
Total operating expenses		44,325				50,434				133,602				143,357
Loss from operations		(3,991	)			(8,637	)			(26,730	)			(17,796	)
Other expense, net		(962	)			(650	)			(2,847	)			(1,151	)
Loss before income tax expense		(4,953	)			(9,287	)			(29,577	)			(18,947	)
Income tax expense (benefit)		(4	)			75				16				151
Net loss	$	(4,949	)		$	(9,362	)		$	(29,593	)		$	(19,098	)
Basic and diluted net loss per share	$	(0.11	)		$	(0.25	)		$	(0.71	)		$	(0.51	)
Weighted average shares used in computing net loss per share:
Basic and diluted		44,012				37,842				41,442				37,387

ATRICURE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands)
(Unaudited)
	September 30,				December 31,
	2020				2019
Assets
Current assets:
Cash, cash equivalents, and short-term investments	$	233,069			$	81,801
Accounts receivable, net		25,448				28,046
Inventories		34,326				29,414
Prepaid and other current assets		3,369				3,899
Total current assets		296,212				143,160
Property and equipment, net		29,089				32,646
Operating lease right-of-use assets		2,363				4,032
Long-term investments		16,516				12,675
Goodwill and intangible assets, net		363,218				364,662
Other noncurrent assets		399				705
Total assets	$	707,797			$	557,880
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued liabilities	$	32,684			$	47,698
Other current liabilities and current maturities of debt and leases		12,070				2,218
Total current liabilities		44,754				49,916
Long-term debt		49,985				59,634
Finance lease liabilities		11,172				11,774
Operating lease liabilities		1,324				2,796
Contingent consideration and other noncurrent liabilities		183,030				186,417
Total liabilities		290,265				310,537
Stockholders' equity:
Common stock		45				40
Additional paid-in capital		729,220				529,658
Accumulated other comprehensive income (loss)		57				(158	)
Accumulated deficit		(311,790	)			(282,197	)
Total stockholders' equity		417,532				247,343
Total liabilities and stockholders' equity	$	707,797			$	557,880

ATRICURE, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP RESULTS TO NON-GAAP RESULTS
(In Thousands)
(Unaudited)
Reconciliation of Non-GAAP Adjusted Income (Loss) (Adjusted EBITDA)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2020				2019				2020				2019
Net loss, as reported	$	(4,949	)		$	(9,362	)		$	(29,593	)		$	(19,098	)
Income tax expense (benefit)		(4	)			75				16				151
Other expense, net		962				650				2,847				1,151
Depreciation and amortization expense		2,479				2,393				7,381				6,983
Share-based compensation expense		5,549				4,287				16,126				12,816
Contingent consideration adjustment		192				(3,062	)			(4,854	)			(6,934	)
Acquisition costs		—				2,819				138				3,645
Non-GAAP adjusted income (loss) (adjusted EBITDA)	$	4,229			$	(2,200	)		$	(7,939	)		$	(1,286	)
Reconciliation of Non-GAAP Adjusted Loss Per Share
	Three Months Ended September 30,								Nine Months Ended September 30,
	2020				2019				2020				2019
Net loss, as reported	$	(4,949	)		$	(9,362	)		$	(29,593	)		$	(19,098	)
Contingent consideration adjustment		192				(3,062	)			(4,854	)			(6,934	)
Net loss excluding contingent consideration adjustment	$	(4,757	)		$	(12,424	)		$	(34,447	)		$	(26,032	)
Basic and diluted adjusted net loss per share	$	(0.11	)		$	(0.33	)		$	(0.83	)		$	(0.70	)
Weighted average shares used in computing adjusted net loss per share
Basic and diluted		44,012				37,842				41,442				37,387